In the first half of 2019, life science companies raised $469m through series A rounds in Europe – a solid start to the year compared to the $686m companies raised in 2018 overall. Silicon Valley Bank expects the European sector to be in “rude health” for the next two to three years at least, when it comes to accessing VC cash.

As health care transitions to digitally enabled wellness, medtechs will be missing a trick if they persist in holding onto the delivery, business methods and models that were the standard of the early 2000s. Heightened expectations of the new options for dealing with personal health mean that new opportunities are there for the taking – but industry shouldn’t let the tech companies have it all their own way, advised ZS principal Brian Chapman.

The complexity of producing viable drug candidates is increasing as an abundance of new science keeps extending the range of possible targets and fragmenting disease subtypes. Proximity to novel exploratory research is a driver of pipeline productivity – so can physical location within a communal geography of well-resourced intellectual firepower raise the odds for R&D success? In Vivo sits down with eight key leaders in academia, VC, commercial real estate and groundbreaking biotech to discuss how Los Angeles – the “out there” city of out-sized ambitions – is positioning itself for global leadership in the curative technologies of the future.

In case you missed it: catch up with snippets from interviews published by In Vivo this week. 

Applied Therapeutics has a business model that defies the conventional wisdom about start-up success: reviving science abandoned by big pharma; financing from a narrow group of investors, dependent on the goodwill of a single academic institution; all in pursuit of a small molecule solution to one of the biggest, diversely complex and cost-defying challenges in chronic disease – the complications of diabetes. 

Applied Therapeutics has a specific entry point to an underserved disease of grinding, irrevocable decline:  diabetic cardiomyopathy as a cause of chronic heart failure (CHF).

In case you missed it: catch up with snippets from interviews published by In Vivo this month.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

The UK continues to build its digital health care infrastructure, as seen in the recent funding pledge for a new AI Lab. Andrew Davies is the newly appointed digital health lead at the UK’s ABHI medtech industry association. He says stakeholders first need to understand the scope of digital health care, and then adopt a networked approach, with medtech playing a full part in that evolution.

A new digital ecosphere to support the efficient delivery of individualized cancer therapies to patients has been released by data and information management company EY. It is an open source framework that can be accessed by all stakeholders in the care delivery chain.

In case you missed it: catch up with snippets from interviews published by In Vivo this week.

Esin Izat, a pharmaceutical marketing research expert, talks to In Vivo about how smaller companies can better utilize pre-launch marketing research and how approaches are changing to reflect new customer profiles and advances in technology.

Biopharma companies raised $12.4bn in Q2, largely from follow-on public offerings. In the latest mega-merger of the year, AbbVie spent $63bn on Allergan and its established portfolio. Many of the higher-valued alliances focused on the area of protein degradation.

AstraZeneca emerged as big pharma’s most active dealmaker over the 2014-2018 period, thanks to a combined surge in both in-licensing and out-licensing agreements.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced August 2019.